Skip to main content
返回讨论

中国作为制药全球创新者的崛起（激励很重要）

Healthcare
全球
开始于 March 24, 2026

This paper examines China’s transition from pharmaceutical “free rider” to global innovator over the last decade. In 2010, China accounted for less than 8% of global clinical trials; by 2020, it had surpassed the US in annual registered clinical trial volume. To study this transformation, we compile a comprehensive, synchronized database spanning the pharmaceutical drug […] The post The rise of China as a global innovator in pharma (incentives matter) appeared first on Marginal REVOLUTION. Re...

来源文章

添加陈述 分析 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
5 条陈述待投票 • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 5/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 发布者 will • Mar 24, 2026
虽然中国在制药领域的增长令人瞩目，但这引发了人们对药物开发中伦理实践和监管监督的担忧。
AI 翻译 · 显示原文

While China's growth in the pharma sector is notable, it raises concerns about ethical practices and regulatory oversight in drug development.

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results
CLAIM 发布者 will • Mar 24, 2026
中国作为制药创新者的崛起是一个积极发展，因为它增强了全球竞争并推低了药物价格。
AI 翻译 · 显示原文

China's rise as a pharmaceutical innovator is a positive development, as it enhances global competition and drives down drug prices.

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results
CLAIM 发布者 will • Mar 24, 2026
临床试验量向中国转移反映了全球化的更广泛趋势，应被视为制药行业的自然演进。
AI 翻译 · 显示原文

The shift in clinical trial volume to China reflects broader trends in globalization and should be seen as a natural evolution in the pharma industry.

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results
CLAIM 发布者 will • Mar 24, 2026
中国在制药领域的快速进步带来了知识产权盗窃的风险，并削弱了全球药物安全的既定标准。
AI 翻译 · 显示原文

China's rapid advancement in pharma poses risks of intellectual property theft and undermines established global standards in drug safety.

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results
CLAIM 发布者 will • Mar 24, 2026
中国向全球制药创新者的转变可能会改善全球医疗成果，惠及世界各地的民众。
AI 翻译 · 显示原文

China's transition to a global innovator in pharmaceuticals could lead to better healthcare outcomes worldwide, benefiting populations everywhere.

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us